Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neuroblastoma 24Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lung Neoplasms 3Leukemia, Myelomonocytic, Juvenile 3Head and Neck Neoplasms 3Uterine Cervical Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Recurrence 2Neoplasms 2Myelodysplastic Syndromes 2Mycosis Fungoides 2Medulloblastoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Myeloid, Acute 2Kidney Neoplasms 2HIV Infections 2Ganglioneuroblastoma 2Central Nervous System Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Burkitt Lymphoma 2Brain Neoplasms 2Acquired Immunodeficiency Syndrome 2AIDS-Related Complex 2Waldenstrom Macroglobulinemia 1Uterine Cervical Dysplasia 1Uterine Cervical Diseases 1Tumor Virus Infections 1Thrombocytopenia 1

Interventions

Cyclophosphamide 7blinatumomab 6Cytarabine 6fludarabine 5Mercaptopurine 5Methotrexate 4fludarabine phosphate 3Vincristine 3Rituximab 3Granulocyte Colony-Stimulating Factor 3Etoposide 3Drug Therapy 3Dexamethasone 3Daunorubicin 3Asparaginase 3Whole-Body Irradiation 2Vindesine 2Thioguanine 2Teniposide 2Stem Cell Transplantation 2Prednisolone 2N,N-dicyclohexyl-isoborneol-10-sulfonamide 2Interleukin-2 2Doxorubicin 2Cladribine 2Blood Specimen Collection 2Azacitidine 2tisagenlecleucel 1thymoglobulin 1sargramostim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Neoplasm, Residual × Isotretinoin × Clear all
NCT02169609 2024-04-22

Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

Fundació Sant Joan de Déu

Phase 2 Completed
24 enrolled
CNS

Neuroblastoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡